EnClear Therapies

EnClear Therapies, founded in 2019 and based in Cambridge, USA, is a private, pre-revenue biotech company developing a novel platform for CNS drug delivery. Its core technology, the EnTrega CSF Platform, is designed to enable controlled, continuous, and personalized delivery of therapeutics directly into the cerebrospinal fluid (CSF), aiming to overcome the blood-brain barrier and improve efficacy while reducing systemic toxicity. The company's initial focus is on addressing a significant unmet need in neuro-oncology, specifically leptomeningeal carcinomatosis, with plans to expand into broader neurodegenerative and rare CNS disorders through strategic partnerships.

The EnTrega CSF Platform is a proprietary system designed for closed-loop control of cerebrospinal fluid (CSF), enabling controlled, continuous, and personalized delivery of therapeutics directly to the CNS. It integrates delivery mechanisms with ML/AI for precision dosing, aiming to bypass the blood-brain barrier, achieve efficacious drug levels at the disease site, and reduce peripheral toxicity.

EnClear operates in the niche of direct CNS drug delivery, competing with other intrathecal infusion technologies, convection-enhanced delivery (CED) systems, and emerging modalities like focused ultrasound. Its differentiation lies in its proposed closed-loop, AI-integrated system for precision dosing and monitoring, positioning it as a potential next-generation solution beyond simple infusion pumps.